← All trials
NCT05275972
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2022
- Primary completion
- Feb 28, 2026
- Completion date
- Dec 31, 2026
- First posted
- Mar 11, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- University of PennsylvaniaCollaborator
- Case Western Reserve UniversityCollaborator
- Dartmouth UniversityCollaborator
- Oregon Health and Science UniversityCollaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityReponsible party - principal investigator
- University of California, DavisCollaborator
- University of California, San FranciscoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.